What is Ninlaro used for?
Ninlaro (ixazomib citrate) is a proteasome inhibitor used to treat patients with multiple myleoma. Multiple myeloma is a type of cancer of the bone marrow, which occurs when plasma cells grow uncontrolled.
Ninlaro comes in the from of a capsule. The Food and Drug Administration (FDA) has specifically approved Ninlaro for use in combination with a thalidomide analog called lenalidomide (Revlimid) and dexamethasone, a corticosteroid. Ninlaro is used in multiple myleoma patients who have received at least one prior therapy.
Ninlaro works by preventing the break down of all the 'garbage' proteins that myeloma cell generate, which leads to them building up and killing the myeloma cells.
Ninlaro is made by Takeda.
- Food and Drug Administration (FDA). Ninlaro. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208462s006lbl.pdf. [Accessed February 4, 2021].
- Multiple Myeloma Research Foundation (MMRF). Proteasome inhibitors. April 25, 2017. Available from: https://themmrf.org/2017/04/25/proteasome-inhibitors/. [Accessed February 4, 2021].
Related Medical Questions
- How much does Ninlaro cost compared to other chemo drugs?
- Ninlaro vs Velcade, which is better?
- Is Ninlaro (ixazomib) a chemotherapy drug? How does it work?
- Does Ninlaro cause shingles (herpes zoster)?
- How effective is Ninlaro (ixazomib)?
- Ninlaro Information for Consumers
- Ninlaro Information for Healthcare Professionals (includes dosage details)
- Side Effects of Ninlaro (detailed)